

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

### SECTION 1. IDENTIFICATION

Product name : Ertugliflozin (< 2%) / Sitagliptin Formulation  
Other means of identification : No data available

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the Hazardous Products Regulations

Skin irritation : Category 2  
Eye irritation : Category 2A  
Skin sensitization : Category 1  
Specific target organ toxicity : Category 2 (Kidney, Stomach, Prostate)  
- repeated exposure (Oral)

#### GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H315 Causes skin irritation.  
H317 May cause an allergic skin reaction.  
H319 Causes serious eye irritation.  
H373 May cause damage to organs (Kidney, Stomach, Prostate) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**  
P260 Do not breathe dust.  
P264 Wash skin thoroughly after handling.  
P272 Contaminated work clothing should not be allowed out of the workplace.  
P280 Wear protective gloves, eye protection and face protec-

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version 5.1      Revision Date: 09/30/2023      SDS Number: 595267-00020      Date of last issue: 03/06/2023  
Date of first issue: 04/04/2016

tion.

### Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P314 Get medical attention if you feel unwell.

P333 + P313 If skin irritation or rash occurs: Get medical attention.

P337 + P313 If eye irritation persists: Get medical attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

### Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

### Other hazards

May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Sitagliptin	No data available	654671-77-9	$\geq 30 - < 60$ *
Cellulose	No data available	9004-34-6	$\geq 30 - < 60$ *
Ertugliflozin	No data available	1210344-83-4	$\geq 1 - < 5$ *
Magnesium stearate	Octadecanoic acid, magnesium salt (2:1)	557-04-0	$\geq 1 - < 5$ *
Propyl 3,4,5-trihydroxybenzoate	Benzoic acid, 3,4,5-trihydroxy-, propyl ester	121-79-9	$\geq 0.1 - < 1$ *

\* Actual concentration or concentration range is withheld as a trade secret

## SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

- |   |   |  |
|---|---|--|
|   |   | for at least 15 minutes while removing contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse.             |
| In case of eye contact                                      | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.<br>If easy to do, remove contact lens, if worn.<br>Get medical attention.                   |
| If swallowed  | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention if symptoms occur.<br>Rinse mouth thoroughly with water.  |
| Most important symptoms and effects, both acute and delayed | : | Causes skin irritation.<br>May cause an allergic skin reaction.<br>Causes serious eye irritation.<br>May cause damage to organs through prolonged or repeated exposure if swallowed. |
| Protection of first-aiders                                  | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).          |
| Notes to physician  | : | Treat symptomatically and supportively.  |

### SECTION 5. FIRE-FIGHTING MEASURES

- |  |   |   |
|--|---|---|
| Suitable extinguishing media                   | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical  |
| Unsuitable extinguishing media                 | : | None known.   |
| Specific hazards during fire fighting          | : | Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.<br>Exposure to combustion products may be a hazard to health.                   |
| Hazardous combustion products                  | : | Carbon oxides<br>Metal oxides<br>Oxides of phosphorus   |
| Specific extinguishing methods                 | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.<br>Use water spray to cool unopened containers.<br>Remove undamaged containers from fire area if it is safe to do so.<br>Evacuate area. |
| Special protective equipment for fire-fighters | : | In the event of fire, wear self-contained breathing apparatus.<br>Use personal protective equipment.  |

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- |   |   |  |
|---|---|--|
| Personal precautions, protective equipment and emergency procedures | : | Use personal protective equipment.<br>Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
|---|---|--|

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version 5.1      Revision Date: 09/30/2023      SDS Number: 595267-00020      Date of last issue: 03/06/2023  
Date of first issue: 04/04/2016

- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of	Control parameters / Permissible	Basis
------------	---------	------------------------	----------------------------------	-------

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version 5.1      Revision Date: 09/30/2023      SDS Number: 595267-00020      Date of last issue: 03/06/2023  
Date of first issue: 04/04/2016

		exposure)	concentration	
Sitagliptin	654671-77-9	TWA	0.5 mg/m <sup>3</sup> (OEB 2)	Internal
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Total dust)	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m <sup>3</sup>	CA BC OEL
		TWAEV (total dust)	10 mg/m <sup>3</sup>	CA QC OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Ertugliflozin	1210344-83-4	TWA	10 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWAEV	10 mg/m <sup>3</sup>	CA QC OEL
		TWA (Inhalable)	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (Respirable)	3 mg/m <sup>3</sup>	CA BC OEL
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

Skin and body protection	: potential for direct contact to the face with dusts, mists, or aerosols. : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: powder
Color	: No data available
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: Not applicable
Evaporation rate	: Not applicable
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: Not applicable

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

### SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

### **Product:**

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

### **Components:**

#### **Sitagliptin:**

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg  
LD50 (Mouse): 3,000 mg/kg

#### **Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

#### **Ertugliflozin:**

Acute oral toxicity : LD50 (Rat): 500 mg/kg  
Acute inhalation toxicity : Remarks: No data available  
Acute dermal toxicity : Remarks: No data available

#### **Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

#### **Propyl 3,4,5-trihydroxybenzoate:**

Acute oral toxicity : LD50 (Mouse, female): > 1,000 - 2,000 mg/kg  
Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

#### **Skin corrosion/irritation**

Causes skin irritation.



# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

---

### **Components:**

#### **Sitagliptin:**

Species	:	Rabbit
Method	:	Draize Test
Result	:	No skin irritation

#### **Ertugliflozin:**

Result	:	Corrosive
--------	---	-----------

#### **Magnesium stearate:**

Species	:	Rabbit
Result	:	No skin irritation
Remarks	:	Based on data from similar materials

#### **Propyl 3,4,5-trihydroxybenzoate:**

Species	:	reconstructed human epidermis (RhE)
Method	:	OECD Test Guideline 439
Result	:	No skin irritation

### **Serious eye damage/eye irritation**

Causes serious eye irritation.

### **Components:**

#### **Sitagliptin:**

Species	:	Rabbit
Result	:	Irritating to eyes.
Method	:	Draize Test

#### **Ertugliflozin:**

Result	:	Severe irritation
--------	---	-------------------

#### **Magnesium stearate:**

Species	:	Rabbit
Result	:	No eye irritation
Remarks	:	Based on data from similar materials

#### **Propyl 3,4,5-trihydroxybenzoate:**

Species	:	Rabbit
Result	:	Irreversible effects on the eye
Method	:	OECD Test Guideline 405

### **Respiratory or skin sensitization**

#### **Skin sensitization**

May cause an allergic skin reaction.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

### Respiratory sensitization

Not classified based on available information.

#### Components:

##### Sitagliptin:

Test Type	: Local lymph node assay (LLNA)
Species	: Mouse
Method	: OECD Test Guideline 429
Result	: Not a skin sensitizer.

##### Ertugliflozin:

Test Type	: Local lymph node assay (LLNA)
Result	: Not a skin sensitizer.

##### Magnesium stearate:

Test Type	: Maximization Test
Routes of exposure	: Skin contact
Species	: Guinea pig
Method	: OECD Test Guideline 406
Result	: negative
Remarks	: Based on data from similar materials

##### Propyl 3,4,5-trihydroxybenzoate:

Test Type	: Local lymph node assay (LLNA)
Routes of exposure	: Skin contact
Species	: Mouse
Result	: positive

Assessment	: Probability or evidence of skin sensitization in humans
------------	---

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Sitagliptin:

Genotoxicity in vitro	: Test Type: Ames test Result: negative
-----------------------	--

	Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells Result: negative
--	--

	Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Test system: rat hepatocytes Result: negative
--	---

Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse
----------------------	--

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

Application Route: Oral  
Result: negative

### Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

### Ertugliflozin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Rat  
Result: negative

### Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

### Propyl 3,4,5-trihydroxybenzoate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: positive

Test Type: Chromosome aberration test in vitro  
Result: positive

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Result: negative

Test Type: In vitro sister chromatid exchange assay in mammalian cells  
Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Sitagliptin:

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Rat  
Application Route : oral (drinking water)  
Exposure time : 2 Years  
Result : positive  
Target Organs : Liver  
Remarks : Significant toxicity observed in testing

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

#### Cellulose:

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

#### Ertugliflozin:

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

### Propyl 3,4,5-trihydroxybenzoate:

Species : Rat  
Application Route : Ingestion  
Exposure time : 103 weeks  
Result : negative

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Sitagliptin:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL Parent: 1,000 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Teratogenicity: LOAEL: 250 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Embryo-fetal development  
Species: Rabbit  
Teratogenicity: NOAEL: 125 mg/kg body weight  
Result: No teratogenic effects.

#### Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

#### Ertugliflozin:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 250 mg/kg body weight  
Remarks: Maternal toxicity observed.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

No significant adverse effects were reported

Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Oral  
Fertility: NOAEL: 200 mg/kg body weight  
Remarks: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 50 mg/kg body weight  
Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 250 mg/kg body weight  
Remarks: No significant adverse effects were reported

### Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### Propyl 3,4,5-trihydroxybenzoate:

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

May cause damage to organs (Kidney, Stomach, Prostate) through prolonged or repeated exposure if swallowed.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

### Components:

#### **Ertugliflozin:**

Routes of exposure	: Oral
Target Organs	: Kidney, Stomach, Prostate
Assessment	: May cause damage to organs through prolonged or repeated exposure.

### **Repeated dose toxicity**

#### Components:

##### **Sitagliptin:**

Species	: Mouse
NOAEL	: 500 mg/kg
LOAEL	: 1,000 mg/kg
Application Route	: Oral
Exposure time	: > 2 y
Target Organs	: Kidney

Species	: Rat
NOAEL	: 500 mg/kg
LOAEL	: 1,000 mg/kg
Application Route	: Oral
Exposure time	: 14 Weeks
Target Organs	: Liver, Kidney, Heart, Teeth

Species	: Dog
NOAEL	: 10 mg/kg
LOAEL	: 50 mg/kg
Application Route	: Oral
Exposure time	: 53 Weeks
Target Organs	: Central nervous system
Symptoms	: Loss of balance
Remarks	: The mechanism or mode of action may not be relevant in humans.

Species	: Dog
NOAEL	: 2 mg/kg
LOAEL	: 10 mg/kg
Application Route	: Oral
Exposure time	: 27 Weeks
Target Organs	: Skeletal muscle, Central nervous system
Symptoms	: Loss of balance
Remarks	: The mechanism or mode of action may not be relevant in humans.

Species	: Monkey
NOAEL	: 100 mg/kg
Application Route	: Oral
Exposure time	: 14 Weeks
Remarks	: No significant adverse effects were reported

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

### Cellulose:

Species	: Rat
NOAEL	: >= 9,000 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

### Ertugliflozin:

Species	: Rat
LOAEL	: 500 mg/kg
Application Route	: Oral
Exposure time	: 30 d

Species	: Rat
LOAEL	: 250 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Kidney

Species	: Rat
LOAEL	: 25 mg/kg
Application Route	: Oral
Exposure time	: 180 d
Target Organs	: Kidney, Bone, Stomach

Species	: Rat
LOAEL	: 25 mg/kg
Exposure time	: 90 d
Target Organs	: Kidney, Gastrointestinal tract, Prostate

Species	: Dog
NOAEL	: 150 mg/kg
Application Route	: Oral
Exposure time	: 270 d
Remarks	: No significant adverse effects were reported

Species	: Mouse
NOAEL	: 100 mg/kg
Application Route	: Oral
Exposure time	: 90 d
Remarks	: No significant adverse effects were reported

Species	: Mouse
NOAEL	: 100 mg/kg
Application Route	: Oral
Exposure time	: 28 d
Target Organs	: Bone
Remarks	: No significant adverse effects were reported

### Magnesium stearate:

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion



# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

Exposure time : 90 Days  
Remarks : Based on data from similar materials

### Propyl 3,4,5-trihydroxybenzoate:

Species : Rat  
NOAEL : 135 mg/kg  
Application Route : Ingestion  
Exposure time : 13 Weeks

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

#### Sitagliptin:

Inhalation : Symptoms: upper respiratory tract infection, pharyngitis, Headache  
Ingestion : Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhea

#### Ertugliflozin:

Ingestion : Symptoms: The most common side effects are:, Headache, constipation, Diarrhea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

#### Sitagliptin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 60 mg/l  
aquatic invertebrates  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic : EC50 (Pseudokirchneriella subcapitata (green algae)): > 39  
plants  
mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201  
  
NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2  
mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox- : NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

icity) Exposure time: 33 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 9.8 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 150 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 150 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition

### Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

### Ertugliflozin:

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 50 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 2.14 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211  
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

### Magnesium stearate:

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

- Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.
- Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.
- NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials
- Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
Exposure time: 16 h  
Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

### Propyl 3,4,5-trihydroxybenzoate:

- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 19.06 mg/l  
Exposure time: 48 h  
Test substance: Neutralized product  
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): 0.37 mg/l  
Exposure time: 72 h  
Test substance: Neutralized product  
Method: OECD Test Guideline 201
- EC10 (Pseudokirchneriella subcapitata (green algae)): 0.17 mg/l  
Exposure time: 72 h  
Test substance: Neutralized product  
Method: OECD Test Guideline 201
- Toxicity to microorganisms : EC50: 636 mg/l  
Exposure time: 3 h  
Method: OECD Test Guideline 209

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

---

### Persistence and degradability

#### Components:

##### **Sitagliptin:**

Biodegradability : Result: not rapidly degradable  
Biodegradation: 39.7 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(401 d)  
Method: OECD Test Guideline 111

##### **Cellulose:**

Biodegradability : Result: Readily biodegradable.

##### **Ertugliflozin:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 40.8 %  
Exposure time: 28 d

##### **Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

##### **Propyl 3,4,5-trihydroxybenzoate:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 49.4 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301F

### Bioaccumulative potential

#### Components:

##### **Sitagliptin:**

Partition coefficient: n-octanol/water : log Pow: -0.03

##### **Ertugliflozin:**

Partition coefficient: n-octanol/water : log Pow: 2.47

##### **Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

##### **Propyl 3,4,5-trihydroxybenzoate:**

Partition coefficient: n-octanol/water : log Pow: 1.8  
Remarks: Calculation

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

### Mobility in soil

#### Components:

##### **Sitagliptin:**

Distribution among environmental compartments : log Koc: 4.37

##### **Ertugliflozin:**

Distribution among environmental compartments : log Koc: 2.88

#### **Other adverse effects**

No data available

## SECTION 13. DISPOSAL CONSIDERATIONS

### **Disposal methods**

Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

## SECTION 14. TRANSPORT INFORMATION

### **International Regulations**

#### **UNRTDG**

Not regulated as a dangerous good

#### **IATA-DGR**

Not regulated as a dangerous good

#### **IMDG-Code**

Not regulated as a dangerous good

#### **Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

### **Domestic regulation**

#### **TDG**

Not regulated as a dangerous good

#### **Special precautions for user**

Not applicable

## SECTION 15. REGULATORY INFORMATION

### **The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

IECSC : not determined

### SECTION 16. OTHER INFORMATION

#### Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	: Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	: Canada. British Columbia OEL
CA QC OEL	: Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for air-borne contaminants
ACGIH / TWA	: 8-hour, time-weighted average
CA AB OEL / TWA	: 8-hour Occupational exposure limit
CA BC OEL / TWA	: 8-hour time weighted average
CA QC OEL / TWAEV	: Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/06/2023
5.1	09/30/2023	595267-00020	Date of first issue: 04/04/2016

---

compile the Material Safety  
Data Sheet

eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date	:	09/30/2023
Date format	:	mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8